Frequency’s long-term hearing loss readout points to hair cell regeneration

Frequency’s data showing its hearing loss therapy can sustain improvements in word recognition for over a year back the product’s potential to regenerate lost hair cells, Chief Development Officer Carl LeBel told BioCentury.

Frequency Therapeutics Inc. (NASDAQ:FREQ) gained 19% Monday, and held the gain Tuesday, on data from an extension study of a Phase I/II trial showing three patients maintained statistically significant improvements in word recognition 13-21 months after a single dose of FX-322. A fourth patient continued to show a numerical improvement, but it was no longer significant...